 | |
| Combination of | |
|---|---|
| Trifluridine | Cytotoxin |
| Tipiracil | Thymidine phosphorylase inhibitor |
| Clinical data | |
| Trade names | Lonsurf |
| Other names | TAS-102 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a615049 |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Trifluridine/tipiracil (FTD–TPI), sold under the brand name Lonsurf, is a fixed-dose combination medication that is used as a third- or fourth-line treatment of metastatic colorectal cancer or gastric cancer, after chemotherapy and targeted therapeutics have failed.[5][6] It is a combination of two active pharmaceutical ingredients: trifluridine, a nucleoside analog, and tipiracil, a thymidine phosphorylase inhibitor.[5][6] Tipiracil prevents rapid metabolism of trifluridine, increasing the bioavailability of trifluridine.[4]
The most common side effects include neutropenia (low levels of neutrophils, a type of white blood cell that fights infection), feeling sick, tiredness and anemia (low red blood cell counts).[4][5][6]
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
- ^ "Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
- ^ "Regulatory Decision Summary for Lonsurf". 23 October 2014.
- ^ a b c "UK Label: Lonsurf - Summary of Product Characteristics". Electronic Medicines Compendium. August 2017. Retrieved 10 May 2018.
- ^ a b c d "Lonsurf- trifluridine and tipiracil tablet, film coated". DailyMed. 14 January 2020. Retrieved 20 October 2020.
- ^ a b c d "Lonsurf EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 20 October 2020.